SR 202

Key Product Details

Product Description

SR 202 is a selective PPARγ antagonist; antidiabetic and antiobesity agent. Attenuates troglitazone-induced PPARγ transcriptional activity (IC₅₀ = 140 μM) without affecting ligand-stimulated PPARα, PPARβ or FXR transcriptional activity. Inhibits PPARγ-dependent adipocyte differentiation and growth in vitro and in vivo. Improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo.

Product Specifications for SR 202

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SR 202

The following data is based on the product molecular weight 358.65.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.79 mL	13.94 mL	27.88 mL
5 mM	0.56 mL	2.79 mL	5.58 mL
10 mM	0.28 mL	1.39 mL	2.79 mL
50 mM	0.06 mL	0.28 mL	0.56 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 335 publications citing the usage of this product.

• Rieusset A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol.Endocrinol. 2002 PMID: 12403851
• Doggrell Do peroxisome proliferation receptor-γ antagonists have clinical potential as combined antiobesity and antidiabetic drugs? Expert.Opin.Invest.Drugs
• Nguyen gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity. J.Med.Chem. 1987 PMID: 3612689

Product Documents for SR 202